http://dx.doi.org/10.1016/S0140-6736(09)61252-6

122. Rennard S, Donohue J, Bateman E, Gross N, Garcia-Gil E, Caracta C. ACCLAIM/COPD II: Efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist in COPD patients, a Phase III study. *Eur Respir J* 2009;**34**(Suppl 53):777s.
123. Jones P, Agusti J, Chanez P, *et al*. Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD. *Eur Respir J* 2009;**34**(Suppl 53):345s.
124. Vestbo J, Vogelmeier C, Creemers J, Ribera A, Garcia-Gil E. Rate of onset of action of aclidinium bromide, a novel, long-acting muscarinic antagonist. *Eur Respir J* 2009;**34**(Suppl 53):779s.
125. Aaron SD, Vandemheen KL, Fergusson D, *et al*. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2007;**146**(8):545-55.
126. de Marco R, Accordini S, Cerveri I, *et al*. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. *Thorax* 2004;**59**(2):120-5. http://dx.doi.org/10.1136/thorax.2003.011163
127. Calverley PM. COPD: early detection and intervention. *Chest* 2000;**117**(5 Suppl 2):365S-71S. http://dx.doi.org/10.1378/chest.117.5_suppl_2.365S
128. Miravitlles M, De la RC, Naberan K, Lamban M, Gobartt E, Martin A, Chapman KR. Attitudes toward the diagnosis of chronic obstructive pulmonary disease in primary care. *Arch Bronconeumol* 2006;**42**(1):3-8. http://dx.doi.org/10.1016/S1579-2129(06)60106-7
129. van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. *Br Med J* 2002;**324**:1370-4.
130. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. *Chest* 2004;**125**(4):1394-9. http://dx.doi.org/10.1378/chest.125.4.1394
131. Kaufmann M, Hartl S, Geyer K, Breyer MK, Burghuber OC. Measuring FEV(6) for detecting early airway obstruction in the primary care setting. Quality and utility of the new PiKo-6 device. *Respiration* 2009;**78**(2):161-7. http://dx.doi.org/10.1159/000197466
132. Price D, Crockett A, Arne M, *et al*. Spirometry in primary care case-identification, diagnosis and management of COPD. *Prim Care Resp J* 2009;**18**(3):216-23. http://dx.doi.org/10.4104/pcrj.2009.00055
133. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. *Chest* 2005;**128**(5):3198-204. http://dx.doi.org/10.1378/chest.128.5.3198
134. George J, Kong DC, Stewart K. Adherence to disease management programs in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2007;**2**(3):253-62.
135. Vestbo J, Anderson JA, Calverley PM, *et al*. Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax* 2009;**64**(11):939-43. http://dx.doi.org/10.1136/thx.2009.113662
136. Celli B. Chronic obstructive pulmonary disease. From unjustified nihilism to evidence-based optimism. *Proc Am Thorac Soc* 2006;**3**:58-65. http://dx.doi.org/10.1513/pats.200510-111JH
137. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. *Am J Respir Crit Care Med* 2009;**180**(1):3-10. http://dx.doi.org/10.1164/rccm.200901-0047OC
138. Barnes PJ, Drazen JM, Rennard SI, Thomson NC. Asthma and COPD, second edition: Basic mechanisms and clinical management.: Academic Press, 2008

CORRIGENDUM

Corrigendum to 'The use of roflumilast in COPD: a primary care perspective' (*Prim Care Resp J* 2010;19(4):342-351)

David Price, Alison Chisholm, Dermot Ryan, Alan Crockett, Rupert Jones

The authors regret that an error occurred in Figure 3 on page 349, which has already been corrected in the online version of the paper:

The text in the first two shaded boxes on the left-hand side of the Figure read:

At risk	**Mild**
• FEV_1/FVC <0.70	• FEV_1/FVC <0.70
• FEV_1 ≥80% predicted	• 50% ≤ FEV_1 <80% predicted

and should read

At risk	**Mild**
• FEV_1/FVC ≥0.70	• FEV_1/FVC <0.70
• FEV_1 ≥80% predicted	• FEV_1 ≥80% predicted

* **Corresponding author:** Professor David Price, Centre of Academic Primary Care, University of Aberdeen, Foresterhill Health Centre, Westburn Road, Aberdeen, Scotland, AB25 2AY, UK. Tel: +44 (0)1224 554588 Fax: +44 (0)1224 840683 E-mail: david@respiratoryresearch.org

DOI of original article: doi:10.4104/pcrj.2010.00066